A major breakthrough has been made in the study of the after-effects of cell therapy stroke in China

Funded by the International Society for Neuroreseciatives China
and chaired by Professor Huang Hongyun, Honorary Director of the Institute of Neurorestepsy at the Third Medical Center of the PLA General Hospital, the clinical trial "Olfactory cells for the treatment of ischemic stroke sequelae" was officially completed, and the results were published online today in the official journal of the International Society for Neurorestebecuitation and the Journal of Neuroresurgery published by Tsinghua University Press.
Huang Hongyun told China News Agency that this is a major breakthrough in the study of the after-effects of cell therapy stroke in China.
Professor Huang Hongyun introduced that the subject is the highest level of evidence-based medical evidence in the multi-center, randomized, double-blind, placebo-controlled clinical trial study, the results show that the olfactory cell therapy control group and the placebo control group compared, in a number of neurofunctoral function evaluation differences; This is by far the world's first positive results report on the highest level of evidence-based medical evidence in clinical cell therapy for neurological diseases, including stroke.
has been exploring clinical treatment of cells of neurological diseases (including various stem cells) for more than 20 years, and although most results have been reported as positive in non-double-blind control studies, there is no evidence-based medical evidence to prove neuro-repair.
The olfactory nerve is the only tissue in the nervous system that can self-regenerate and repair for life, and this important characteristic and ability depends mainly on the powerful support of olfactory cells, but the massive insular amplification of olfactory cells has been an unattriffable technical difficulty. Professor Huang Hongyun's team has worked hard for more than ten years to obtain Chinese and American patents for the core technology of large-scale production of olfactory cells, from cell source production to clinical treatment technology mastering and exploration, standing at the forefront of neuro-repair clinical cell therapy, and realizing the original innovative breakthrough of neuro-damaged sequelae repair treatment from 0 to 1. Professor Huang Hongyun said this major innovation will change the way stroke and neurological diseases are treated, providing healthy China with achievable clinical technical support.